

Review Article



Journal of Biomedical and Pharmaceutical Insights (JBPI)

e-ISSN: Applied For

Volume 1 | Issue 1 | 2026 | Pages 80-90

DOI: To be assigned

<https://jbpijournal.org>***NANO MEDICINE FOR OCULAR DRUG DELIVERY*****¹G. Sai Teja, ²T. Gayathri, ³N. Nithin, ⁴D. Soujanya, ⁵R. Rajitha**¹B. Pharmacy IV Year, CVM College of Pharmacy, Velichala, Karimnagar, India.²Assistant Professor, University College of Pharmaceutical Sciences, Satavahana University, Karimnagar, India.³B. Pharmacy IV Year, CVM College of Pharmacy, Velichala, Karimnagar, India.⁴Assistant Professor, CVM College of Pharmacy, Velichala, Karimnagar, India.⁵Assistant Professor, University College of Pharmaceutical Sciences, Satavahana University, Karimnagar, India.**ABSTRACT:**

Ocular drug delivery remains a major challenge due to the eye's complex anatomical and physiological barriers, which significantly limit drug penetration and bioavailability. Conventional ocular dosage forms such as eye drops exhibit poor therapeutic efficiency, with less than 5% of the administered dose reaching the target site because of rapid tear turnover, nasolacrimal drainage and corneal barriers. Management of chronic ocular diseases often requires frequent dosing, resulting in poor patient compliance, local irritation and systemic side effects. Delivering drugs to the posterior segment of the eye is even more difficult because of the blood-retinal barrier, while invasive approaches like intravitreal injections are associated with complications such as retinal detachment, haemorrhage and infection. Nanotechnology-based ocular drug delivery systems have emerged as a promising strategy to overcome these limitations. Nanocarriers, including liposomes, polymeric nanoparticles, nano micelles and solid lipid nanoparticles, improve drug stability, improve corneal penetration, prolong precorneal retention time and provide sustained mucoadhesive polymers and targeting ligands further enhancing site-specific delivery to both anterior and posterior ocular tissues. Thus, nanomedicine offers a transformative approach for improving ocular therapeutics, increasing patient compliance and achieving more effective management of ocular diseases.

Key Words: Nanomedicine, Ocular bioavailability, Blood-retinal barrier, Corneal penetration.

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Copyright © 2026 The Author(s).

Received: 29-05-2026
Revised: 05-06-2026
Accepted: 07-06-2026
Published : 11-06-2026

Corresponding Author : G. Sai Teja
Email Id : saitejagoudguttamidi@gmail.com

INTRODUCTION:

The human eye is a highly protected organ, isolated from the external environment and systemic circulation by a complex network of anatomical and physiological barriers. While these mechanisms efficiently safeguard the eye from pathogens and foreign matter, they present a formidable challenge to ocular therapeutics. Conventional dosage forms, such as topical eye drops, suffer from extremely low ocular bioavailability, typically retaining **less than 5% of the administered dose**. The rapid turnover pre-corneal tear film reflects junction rapidly eliminate topically applied foreign compose consequently managing chronic ocular diseases requires frequent high-dose applications, which often lead to poor patient compliance, local irritation, and potential systemic toxicity via nasolacrimal mucosal absorption.

Nano medicine for ocular drug delivery uses nanoscale carriers (10 to 400 nm) to overcome the eye's natural anatomical barriers, significantly increasing bioavailability and enabling sustained drug release.

Treating pathologies of the posterior segment of the eye, such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma, presents an even greater clinical hurdle. Due to the presence of the blood-retinal barrier (BRB), systemic drug administration cannot reach therapeutic in the retina without causing severe systemic side effects. While intravitreal injections deliver drugs directly to the posterior chamber, this invasive procedure carries serious risks, including endophthalmitis, retinal detachment, vitreous haemorrhage, significant patient discomfort from recurring injections.

To overcome these critical limitations, *nanomedicine has emerged as a transformative frontier in ocular drug delivery*. Utilizing engineered nanomaterial ranging from 10 to 1000 nanometres allows for unprecedented control over drug pharmacokinetics and biodistribution. Nanocarriers-including liposomes, polymeric nanoparticles, nano micelles, and solid lipid nanoparticles-can shield encapsulated therapeutics from enzymatic degradation, improve

corneal penetration through endocytic pathways, and provide sustained drug release over extended periods. Furthermore, functionalising nanoparticle surfaces with mucoadhesive polymers or targeting ligands enhances precorneal retention time and enable site-specific delivery, effectively bridging the gap between front and back-of-the-eye therapies.




Fig 1: Schematic representation of different nanotechnology platforms for ocular drug delivery, highlighting barrier penetration, adhesion, and controlled release triggers.

TYPES OF NANO OCULAR DELIVERY SYSTEMS:

- **Polymeric Nanoparticles:** Solid, sub-micron particles made of natural or synthetic polymers (e.g., PLGA, Chitosan) that encapsulate drugs, protecting them from degeneration and enabling controlled release.




Fig 2: Classification of organic and inorganic nanoparticles for ocular drug delivery, with respective size ranges and primary administration routes.

- **Liposomes and Niosomes:** Vesicular structures consisting of aqueous cores surrounded by lipid bilayers. Ideal for co-delivering both hydrophilic and hydrophobic drugs.
- **Nano Emulsions:** Transparent, thermodynamically stable or semi-stable oil-in-water or water-in-oil dispersion, highly useful for enhancing the ocular solubility of hydrophobic ophthalmic drugs.
- **Nano Micelles:** self-assembling amphiphilic structures that form in aqueous media, creating a hydrophobic core for drug loading and a hydrophilic shell for excellent aqueous dispersibility.
- **Nanogels:** Three-dimensional crosslinked polymeric networks that offer stimuli-responsive drug release and high biocompatibility.




Fig 3: Classification of nanotechnology-based ocular drug delivery systems and highlighting FDA-approved products their current clinical/regulatory status.

COMMON PREPARATION METHODS:

- **Solvent Evaporation:** Commonly used for polymeric nanoparticles. The polymer and drug are dissolved in a volatile organic solvent and emulsified in an aqueous phase. The solvent is then evaporated under reduced pressure to leave behind solid nanoparticles.
- **High-Pressure Homogenization:** Highly effective for producing nanosuspensions and nano emulsions. It forces a mixture of the drug, surfactant, and solvent/oil through a thin valve under extreme pressure, breaking particles down to the nanoscale.
- **Thin-Film Hydration:** The standard methods for creating liposomes. Lipids and drugs are dissolved in an organic solvent, which is evaporated to form a thin lipid film. The film is then hydrated with an aqueous buffer to form vesicles.

- **Nanoprecipitation (Solvent Displacement):** A simple one-step method where the polymer and drug are dissolved in a water-miscible organic solvent. This solution is injected dropwise into a non-solvent (often water) containing a stabiliser, prompting instant nanoprecipitation.
- **Self-Assembly /Solvent Casting:** Used for micelles and cubosomes, where amphiphilic molecules spontaneously self-assemble in an aqueous solution as their concentration crosses the critical micellar concentration (CMC).




Fig 4: Schematic flowchart illustrating the formulation development and physicochemical characterization.

ADMINISTRATION ROUTES:

- **Topical Application:** The most common, non-invasive route. Nano-formulations-especially cationic (Positively charged) ones-increase mucoadhesion and retention time on the corneal surface, allowing better drug penetration into ocular tissues.
- **Intravitreal Injection:** Direct injection into the vitreous humour to bypass anterior barriers, primarily utilized for treating posterior segment disease like age-related macular degeneration.
- **Periocular/Subconjunctival:** Injection into the tissues surrounding the eye. This provides sustained drug release and allows the drug to diffuse across the sclera, reaching the posterior segment without piercing the globe.

EVALUATION PARAMETERS:

Evaluating nano-ocular drug delivery systems requires a combination of physiochemical characterization and ocular tolerance & comfort parameters. Critical parameters ensure nanocarriers like liposomes, nano emulsions, or polymeric nano particles can bypass eye barriers while remaining stable, non-irritating and effective.

1. **Physiochemical Characteristics:** These metrics ensure the nano-formulation is structurally stable, uniform and physically compatible with the eye.
 - **Particle size & Polydispersity Index (PDI):** Size must be <200 nm for optimal corneal penetration. PDI indicates the size distribution; a PDI <0.3 is desired for a uniform formulation.
 - **Zeta Potential:** Measures the surface charge of the nanoparticles. A value of ± 30 mV or higher provides sufficient electrostatic repulsion to prevent aggregation.
 - **Entrapment Efficiency (EE) & Drug Loading:** Qualifies how much active pharmaceutical ingredient is successfully loaded into the nanocarrier, typically assessed by centrifuging or separating the free drug.
 - **Rheology and Viscosity:** Viscosity must be optimized (<20mPa.s) to allow easy instillation from an eye dropper without blurring vision, while ensuring adequate mucoadhesion to increase residence time.
2. **Ocular Tolerance & Comfort Parameters:** These parameters ensure the formulation does not induce blinking pain, tearing or structural damage to the corneal epithelium.

- **pH:** The formulation pH must ideally fall between 7.2 and 7.4 (closely matching tear fluid) to avoid severe irritation.
- **Osmolarity:** Needs to be isotonic to tears. An osmolality within the standard limit (typically 100 to 640 mOsm/kg) prevents osmotic shock to the eye.
- **Surface Tension:** Should be adjusted (ideally lower than convention, but around 40-50 mN/m) to allow the formulation to spread evenly across the tear film.
- **Refractive index & Transmittance:** Essential for clear vision. The formulation must be transparent (high percentage transmittance) to prevent clouded vision upon administration.

ADVANTAGES:

- **Overcoming Ocular Barriers:** The eye naturally flushes out traditional drops via tear dilution and blinking, allowing only 5% of a drug to be observed. Nanocarriers feature high surface-area-to-volume ratios and mucoadhesive properties, which help bypass these protective clearance mechanisms.
- **Sustained Drug Release:** Nanoparticles act as drug reservoirs, slowly releasing their active pharmaceutical ingredients over time. This decreases administration frequency and vastly improves patient compliance.
- **Enhanced Bioavailability:** By improving drug solubility and penetration through both corneal and non-corneal routes, a much higher percentage of the administered dose reaches the intended site of action within the eye.

DISADVANTAGES:

1. Topical Administration (Eye drops & Suspensions)

- **Extremely Low Bioavailability:** Only 1-5% of the drug is absorbed. The rest is wiped away by tear drainage.
- **Frequent Dosing:** because the drug is flushed out quickly, patients often require hourly or multiple daily doses to maintain a therapeutic effect.
- **Systemic Toxicity:** Drainage through the nasolacrimal duct can channel the medication into the blood stream, leading to unwanted side effects.
- **Wasted Medications:** The volume of a standard eye drop often exceeds what the eye can hold, leading to overflow and waste.

2. Ophthalmic Ointments & Gels:

- **Vision Interference:** These formulations are thick and cause temporary blurring or haziness.
- **Messiness:** They can leave a greasy residue around the eyelids and eyelashes.

3. Ocular Inserts & Contact Lenses:

- **Discomfort:** Solid or semi-solid inserts can cause a foreign-body sensation and irritation.
- **Loss or Misplacement:** Inserts may occasionally slip out during or when rubbing the eyes.

4. Intraocular Injections & Implants:

- **Invasiveness:** Procedures requiring intravitreal or subconjunctival injections carry risks of endophthalmitis (severe internal eye inflammation), retinal detachment and haemorrhage.
- **Emergency Termination:** Unlike eye drops that can be easily rinsed out, once an implant or injection is administered, the dosage form cannot be quickly terminated in the event of an adverse reaction.

LIMITATIONS:

1. **Biocompatibility & Toxicity:** Nanocarriers (e.g., lipid or polymer-based nanoparticles, dendrimers) can induce oxidative stress, mitochondrial damage, or severe immunological responses. The sensitive nature of ocular tissues makes the eye highly vulnerable to nanomaterial-induced inflammation.
2. **Rapid Clearance & Low Bioavailability:** Despite nanoscale designs to bypass biological barriers, tear turnover and nasolacrimal drainage often flush nanoparticles away rapidly. This shortens contact time and prevents the maintenance of sustained therapeutic drug levels.
3. **Poor Deep Tissue Penetration:** Nanoparticles face physical stability issues. They are prone to degradation or aggregation over time, which compromises both safety and drug release efficacy.
4. **Manufacturing & Regulatory Hurdles:** Standardizing, scaling up and sterilizing nanomaterials consistently without altering their size, shape or surface charge poses major regulatory and cost challenges.

PHARMACEUTICAL APPLICATIONS:

1. **Segment Disease:** Nano-formulations, particularly nano emulsions and nano micelles, enhance the transcorneal permeation of poorly water-soluble drugs. They are widely used to treat dry eye syndrome (e.g. Cequa and Restasis), glaucoma, and post-operative inflammation by sustaining drug release and reducing dosing frequency.
2. **Posterior Segment Delivery:** Delivering therapeutics to the retina and choroid is traditionally difficult due to the blood-retina barrier. Specially engineered nanoparticles allow for non-invasive, targeted delivery to treat conditions like age-related macular degeneration (AMD) and diabetic retinopathy, potentially replacing invasive intraocular injections.
3. **Gene Therapy:** Viral and non-viral nanocarriers (e.g., lipid nanoparticles and dendrimers) are utilized to transport genetic material to ocular cells. This has clinical applications in treating inherited retinal dystrophies and genetic vision loss.
4. **Ocular Infections & Inflammation:** Nanocarriers can encapsulated anti-infective and anti-inflammatory agents to maintain therapeutic drug concentrations in the conjunctiva and aqueous humour for extended periods, effectively combating bacterial, fungal, and viral infections.
5. **Glaucoma Management:** Glaucoma treatments require continuous, lifelong intraocular pressure (IOP) reduction, which is often hindered poor patient compliance with multiple daily eye drops.
 - **Sustained-Release Nanoparticles:** Polymeric nanoparticles (e.g., using PLA or PLGA) can encapsulated antiglaucoma agents like timolol or brimonidine. They adhere to the negatively charged corneal mucous layer via mucoadhesion, serving as a localized drug depot that steadily release the drug over days or weeks.
6. **Posterior Segment Diseases (AMD and DR):** Treating conditions affecting the retina, such as age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR), usually requires highly invasive intravitreal injections.
 - **Blood-Retinal Barrier (BRB) Penetration:** Nanoparticles can successfully bypass or cross internal static barriers like the BRB.
 - **Injection Frequency Reduction:** Nanomedicines packed into liposomes, dendrimers, or solid lipid nanoparticles significantly prolong the half-life of anti-VEGF agents or corticosteroids inside the vitreous humour. This reduces the clinical need for frequent, painful injections and minimizes risks like retinal detachment or endophthalmitis.

ACKNOWLEDGEMENTS

The authors express their sincere gratitude to CVM College of Pharmacy, Velichala, Karimnagar, Telangana, India, and University College of Pharmaceutical Sciences, Satavahana University, Karimnagar, Telangana, India, for providing academic support, library facilities, and access to scientific resources for the preparation of this review article.

AUTHOR CONTRIBUTIONS

G. Sai Teja: Conceptualization, literature review, data collection, manuscript drafting, and preparation of figures and tables.

Author 2: Literature survey, content validation, and critical review of the manuscript.

Author 3: Data compilation, manuscript editing, and reference management.

Author 4: Scientific review, technical guidance, and manuscript revision.

Author 5: Supervision, final review, and approval of the manuscript for publication.

All authors have read and approved the final version of the manuscript.

FUNDING

No external funding was received for the preparation of this review article.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

DATA AVAILABILITY STATEMENT

No new datasets were generated or analyzed during the preparation of this review article. All information presented in this manuscript has been collected and compiled from previously published scientific literature and publicly available sources.

CORRESPONDING AUTHOR

G. Sai Teja

B. Pharmacy IV Year,
CVM College of Pharmacy,
Velichala, Karimnagar, Telangana, India.
Email: saitejagoudguttamidi@gmail.com

CONCLUSION:

Nanomedicine has emerged as a promising approach for overcoming the limitations of conventional ocular drug delivery systems. The unique anatomical and physiological barriers of the eye often restrict drug penetration and reduce therapeutic efficacy. Nanocarrier-based systems including nanoparticles, liposomes, niosomes, dendrimers, nanomicelles and nanoemulsions, offer significant advantages such as enhanced drug solubility, improved bioavailability, prolonged drug retention, controlled release and targeted delivery to ocular tissues.

Recent advances in nanotechnology have demonstrated the potential of nanomedicines to effectively treat both anterior and posterior segment eye diseases while minimizing systemic exposure and adverse effects. Furthermore, the integration of biodegradable and biocompatible materials has improved the safety and clinical applicability of these systems. Despite encouraging preclinical and clinical outcomes, challenges related to large-scale manufacturing, long-time safety, regulatory approval and cost-effectiveness remain to be addressed.

Overall, nanomedicine represents a transformative strategy in ocular therapeutics, offering improved treatment outcomes and enhanced patient compliance. Continued research and technological advancements are expected to facilitate the translation of innovative nano-based ocular drug delivery systems from laboratory research to clinical practice, ultimately improving the management of various ocular disorders.

REFERENCES:

1. **Li-Ching Liu, Yi-Hao Chen, Da-Wen Lu** Overview of Recent Advances in Nano-Based Ocular Drug Delivery, *International Journal of Molecular Sciences*, 2023.
2. **Suri R., Beg s** Nanoemulsion-Based Ocular Drug Delivery Systems, *Drug Delivery*, 2021.
3. **Agarwal R., Iqbal J., Ali J** Recent Advances in Nanocarrier-Based Ocular Drug Delivery, *Drug discovery Today*, 2020.
4. **Bisht R., Rupenthal ID** Nanoparticle-Based Ocular Drug Delivery Systems, *Journal of Drug Delivery Science and Technology*, 2019;49:291-299.
5. **Awwad S., Lockwood A.**, Nanotechnology in Ocular Drug Delivery Systems, *Pharmaceutics*, 2019.

6. **Wadhwa S., Paliwal R., Paliwal S.R** Nanocarriers in Ocular Drug Delivery: An Update Review, *Current Pharmaceutical Design*, 2018.
7. **Janagam D.R., Wu L., Lowe T.L** Nanoparticles for Drug Delivery to the Anterior Segment of the Eye, *Advanced Drug Delivery Reviews*, 2017.
8. **Yellepeddi V.K., Palakurthi S** Recent Advances in Topical Ocular Drug Delivery, *Journal of Ocular Pharmacology and Therapeutics*, 2016.
9. **Natarajan J.V., Darwitan A., Barathi V.A** Nanomedicine for Glaucoma: Liposomes and Nanoparticles, *Journal of Controlled Release*, 2014.
10. **Raghava S., Hammond M** Nanoparticle-Mediated Ocular Drug Delivery, *Expert Opinion on Drug Delivery*, 2014.
11. **Kaur I.P., kakkar S** Nanotherapy for Posterior Eye Diseases, *Journal of Controlled Release*, 2014.
12. **Yavuz B., Bozdog Pehlivan S., Unlu N** An Overview on Drug Eye Treatment: Approaches for Cyclosporine A Delivery, *Scientific World Journal*, 2012.
13. **Kompella U.B., Kadam R.S., Lee V.H.L** Recent Advances in Ophthalmic Drug Delivery, *Therapeutic Delivery*, 2010.
14. **Diebold Y., Calonge M** Applications of Nanotechnology in Ocular Drug Delivery, *Progress in Retinal and Eye Research*, 2010.
15. **Araujo J., Gonzalez-Mira E** Lipid- Based Nanocarriers for Ocular Drug Delivery, *Current Drug Targets*, 2009.